source
- FDA offers guidance for smoother BLA submissions and outlines biosimilar review changesSubmitting a biologics license application requires early interaction with the FDA's Office of Therapeutic Products, careful preparation to avoid technical and administrative mistakes, and keeping…
- FDA advises early engagement and error prevention for BLA submissions, says CBER expertA CBER specialist shared practical guidance for companies preparing biologics license applications. The expert stressed that early interaction with the FDA’s Office of Therapeutic Products can str…